StreetInsider.com News Articles

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the company’s common stock to 38 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with grant dates and vesting commencement dates ranging from April 7, 2026 through July 8,

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:05:00 -0400

Form 8-K Evolus, Inc. For: Jul 07

Wed, 08 Jul 2026 09:04:00 -0400

si-local-file:///var/storage/secattach/20260708/26745286.html

Form 8-K Evolus, Inc. For: Jul 07

Wed, 08 Jul 2026 09:04:00 -0400

si-local-file:///var/storage/secattach/20260708/26745286.html

Evolus strikes licensing deal with IBSA to bring Profhilo to US

Wed, 08 Jul 2026 09:02:23 -0400

Evolus, Inc. (NASDAQ: EOLS) has entered into an exclusive licensing and distribution agreement with Swiss pharmaceutical company IBSA to develop and commercialize Profhilo®, an injectable skin quality product, in the United States.

Profhilo® is available in more than 70 countries and has recorded more than 4.8 million treatments administered worldwide since its 2015 launch. The product uses a hyaluronic acid formulation intended for superficial application to improve skin hydration, elasticity, and smoothness, distinguishing it from traditional hyaluronic acid injectables designed to restore volume or facial structure.

Under the agreement, Evolus will be responsible for development activities required for U.S. regulatory approval and

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Wed, 08 Jul 2026 09:00:00 -0400

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and commercialize Profhilo® in the United States.

Profhilo® is the market-leading injectable in Europe for skin quality, with global brand recognition and availability in more than 70 countries. Profhilo® has a strong track record of clinical performance and commercial success across international markets, with more than 4.8 million treatments

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Wed, 08 Jul 2026 09:00:00 -0400

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Wed, 08 Jul 2026 09:00:00 -0400

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Wed, 08 Jul 2026 09:00:00 -0400

Form EFFECT Evolus, Inc.

Mon, 15 Jun 2026 06:13:00 -0400

si-local-file:///var/storage/secattach/20260615/26643834.html

Form EFFECT Evolus, Inc.

Mon, 15 Jun 2026 06:13:00 -0400

si-local-file:///var/storage/secattach/20260615/26643834.html

Form 8-K Evolus, Inc. For: Jun 11

Fri, 12 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260612/26641096.html

Form 8-K Evolus, Inc. For: Jun 11

Fri, 12 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260612/26641096.html

Evolus (EOLS) files $250M mixed shelf

Fri, 05 Jun 2026 16:49:55 -0400

Evolus (NASDAQ: EOLS) has filed $250,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants
Units
Rights

Evolus (EOLS) files $250M mixed shelf

Fri, 05 Jun 2026 16:49:55 -0400

Evolus (NASDAQ: EOLS) has filed $250,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants
Units
Rights

Form S-3 Evolus, Inc.

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611868.html

Form S-3 Evolus, Inc.

Fri, 05 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260605/26611868.html

Evolus to Participate in The Jefferies Global Healthcare Conference

Tue, 19 May 2026 08:30:00 -0400

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New York City.

The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM ET.

The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days

Evolus to Participate in The Jefferies Global Healthcare Conference

Tue, 19 May 2026 08:30:00 -0400

The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM ET.

The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days

Evolus to Participate in The Jefferies Global Healthcare Conference

Tue, 19 May 2026 08:30:00 -0400

The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM ET.

The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days

Evolus to Participate in The Jefferies Global Healthcare Conference

Tue, 19 May 2026 08:30:00 -0400

The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM ET.

The fireside chat can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available 90 days

Evolus launches Estyme hyaluronic acid gels in Europe

Mon, 11 May 2026 08:30:22 -0400

Evolus Inc. (NASDAQ: EOLS) announced the commercial launch of its Estyme injectable hyaluronic acid gel collection in Europe on May 16, marking the company's entry into the international dermal filler market.

The Estyme collection includes four injectable hyaluronic acid gels: Estyme Smooth and Estyme Form, currently marketed in the United States under the Evolysse brand, along with two new products, Estyme Lips and Estyme Sculpt. Estyme Sculpt is designed for restoring mid-face volume and is expecting U.S. FDA approval later this year.

The products are developed using Symatese's Cold-X technology, which the company states helps preserve the natural structure of the hyaluronic

Evolus launches Estyme hyaluronic acid gels in Europe

Mon, 11 May 2026 08:30:22 -0400

The products are developed using Symatese's Cold-X technology, which the company states helps preserve the natural structure of the hyaluronic